Amino/Amido Conjugates Form to Nanoscale Cobalt Physiometacomposite (PMC) Materials Functionally Delivering Nucleic Acid Therapeutic to Nucleus Enhancing Anticancer Activity via Ras-Targeted Protein Interference.
Robert K DeLongJohn DeanGarry GlaspellMajid Jaberi-DourakiKartik GhoshDaniel DavisNancy A Monteiro-RiviereParwathy ChandranTuyen NguyenSantosh AryalC Russell MiddaughSeok Chan ParkSeong-O ChoiMeghana RamaniPublished in: ACS applied bio materials (2020)
Aberrant splicing and protein interaction of Ras binding domain (RBD) are associated with melanoma drug resistance. Here, cobalt or nickel doped zinc oxide (ZnO) physiometacomposite (PMC) materials bind to RNA and peptide shown by Ninhydrin staining, UV-vis, Fourier transform infrared, and circular dichroism spectroscopy. PMCs deliver splice switching oligomer (SSO) into melanoma cells or 3-D tumor spheroids shown by flow cytometry, fluorescence microscopy, and bioluminescence. Stability in serum, liver, or tumor homogenate up to 48 h and B16F10 melanoma inhibition ≥98-99% is shown. These data suggest preclinical potential of PMC for delivery of SSO, RBD, or other nucleic acid therapeutic and anticancer peptides.
Keyphrases
- nucleic acid
- flow cytometry
- single molecule
- reduced graphene oxide
- metal organic framework
- quantum dots
- high resolution
- amino acid
- binding protein
- oxide nanoparticles
- carbon nanotubes
- cancer therapy
- energy transfer
- protein protein
- wild type
- atomic force microscopy
- visible light
- gold nanoparticles
- electronic health record
- high throughput
- room temperature
- cell therapy
- high speed
- stem cells
- highly efficient
- machine learning
- drug delivery
- climate change
- mass spectrometry
- single cell
- human health